Pressmeddelanden från QLife

The exercise period for warrants of series TO 5 in Qlife Holding begins today, 21 November 2024

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, ...

The exercise period for warrants of series TO 5 in Qlife Holding begins today, 21 November 2024

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, ...

Ny huvudansvarig revisor för Qlife Holding AB (publ)

Vid årsstämman den 26 juni 2024 valdes Göteborgs Revision Kommanditbolag (”Göteborgs Revision”) till revisionsbolag för Qlife Holding AB (pu...

Ny huvudansvarig revisor för Qlife Holding AB (publ)

Vid årsstämman den 26 juni 2024 valdes Göteborgs Revision Kommanditbolag (”Göteborgs Revision”) till revisionsbolag för Qlife Holding AB (pu...

Qlife announces outcome in directed issues

Qlife announces outcome in directed issues

Qlife announces outcome in directed issues

Qlife announces outcome in directed issues

Bulletin from the extraordinary general meeting, and the second control meeting, in Qlife Holding AB on 8 November 2024

Today, on 8 November 2024, an extraordinary general meeting, and the second control meeting, was held in Qlife Holding AB.

Kommuniké från extra bolagsstämma tillika andra kontrollstämma i Qlife Holding AB den 8 november 2024

Idag, den 8 november 2024, hölls extra bolagsstämma, tillika den andra kontrollstämman, i Qlife Holding AB.

QLIFE HOLDING AB, Interim Report Q3, July to September 2024

Finally there

QLIFE HOLDING AB, Interim Report Q3, July to September 2024

Finally there

Kallelse till extra bolagsstämma i Qlife Holding AB tillika andra kontrollstämma

Aktieägarna i Qlife Holding AB, org.nr 559224-8040 (”Bolaget”), kallas till extra bolagsstämma, tillika andra kontrollstämma, den 8 november...

Kallelse till extra bolagsstämma i Qlife Holding AB tillika andra kontrollstämma

Aktieägarna i Qlife Holding AB, org.nr 559224-8040 (”Bolaget”), kallas till extra bolagsstämma, tillika andra kontrollstämma, den 8 november...

Qlife withdraws proposal to change company name

Qlife Holding AB (publ) (“Qlife” or the “Company”) has decided to withdraw its proposal to change the Company’s name as the intended name, E...

Qlife withdraws proposal to change company name

Qlife Holding AB (publ) (“Qlife” or the “Company”) has decided to withdraw its proposal to change the Company’s name as the intended name, E...

Qlife starts sales of its PHE rare disease test, addressing an unmet need in the at-home testing market worth SEK 2.5 billion

Resent due to technical problems news distributor. Since its inception, Qlife has been developing the Phenylalanine (PHE) test capsule and ...

Qlife starts sales of its PHE rare disease test, addressing an unmet need in the at-home testing market worth SEK 2.5 billion

Resent due to technical problems news distributor. Since its inception, Qlife has been developing the Phenylalanine (PHE) test capsule and ...

Qlife starts sales of its PHE rare disease test, addressing an unmet need in the at-home testing market worth SEK 2.5 billion

Since its inception, Qlife has been developing the Phenylalanine (PHE) test capsule and is now prepared to offer it for sale to individuals ...

Qlife starts sales of its PHE rare disease test, addressing an unmet need in the at-home testing market worth SEK 2.5 billion

Since its inception, Qlife has been developing the Phenylalanine (PHE) test capsule and is now prepared to offer it for sale to individuals ...

Qlife is pleased to announce that Peter Warthoe will return to the management group as Chief Scientific Officer

Peter Warthoe, one of the three founders of Qlife, is back in his management role as Chief Scientific Officer and will focus on the company’...

Qlife is pleased to announce that Peter Warthoe will return to the management group as Chief Scientific Officer

Peter Warthoe, one of the three founders of Qlife, is back in his management role as Chief Scientific Officer and will focus on the company’...

Qlife Holding AB (publ) is pleased to announce that it publishes a second balance sheet for liquidation purposes showing that the Company's total equity exceeds the registered share capital

Qlife Holding AB (publ) (“Qlife” or the “Company”) has, in accordance with Chapter 25, Section 16 of the Swedish Companies Act (“ABL”), prep...

Qlife Holding AB (publ) is pleased to announce that it publishes a second balance sheet for liquidation purposes showing that the Company's total equity exceeds the registered share capital

Qlife Holding AB (publ) (“Qlife” or the “Company”) has, in accordance with Chapter 25, Section 16 of the Swedish Companies Act (“ABL”), prep...

Production of Egoo consumables now established in China to support on-going clinical trials and future sales

Qlife Holding AB (publ) (“Qlife” or the “Company”) recently announced a restructuring and new financing to support its strategic goals.

Production of Egoo consumables now established in China to support on-going clinical trials and future sales

Qlife Holding AB (publ) (“Qlife” or the “Company”) recently announced a restructuring and new financing to support its strategic goals.

Qlife provides strategic business update and plans rebranding as 'Egoo Health' – a new era begins

Qlife Holding AB (publ) ("Qlife" or the "Company") is pleased to announce a comprehensive business update in light of recent strategic devel...

Qlife provides strategic business update and plans rebranding as 'Egoo Health' – a new era begins

Qlife Holding AB (publ) ("Qlife" or the "Company") is pleased to announce a comprehensive business update in light of recent strategic devel...

Qlife acquires the assets of Qlife ApS, carries out directed issues of a total of approx. MSEK 6.90 and proposal of directed issues of approx. MSEK 5.05

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALA...

Qlife acquires the assets of Qlife ApS, carries out directed issues of a total of approx. MSEK 6.90 and proposal of directed issues of approx. MSEK 5.05

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALA...

QLIFE HOLDING AB, Interim Report Q2, April to June 2024

Restructuring the company

QLIFE HOLDING AB, Interim Report Q2, April to June 2024

Restructuring the company

Qlife Holding AB (publ) meddelar omräkning av teckningsoptioner

Med anledning av sammanläggningen av aktier i Qlife Holding AB (publ) (”Qlife” eller ”Bolaget”) som beslutades på årsstämman den 26 juni 202...

Qlife Holding AB (publ) meddelar omräkning av teckningsoptioner

Med anledning av sammanläggningen av aktier i Qlife Holding AB (publ) (”Qlife” eller ”Bolaget”) som beslutades på årsstämman den 26 juni 202...

Qlife Holding AB’s subsidiary Qlife ApS terminates corporate restructuring and files for bankruptcy. Qlife Holding AB investigates a capital raise and to submit an offer to repurchase the assets.

Qlife Holding AB ("Qlife" or the "Company") has today received information that Qlife ApS’s reconstructor will terminate the corporate restr...

Avstämningsdag för sammanläggning av aktier i Qlife Holding AB

Styrelsen i Qlife Holding AB (publ) (”Qlife” eller ”Bolaget”) har, med stöd av bemyndigandet från årsstämman som hölls den 26 juni 2024, bes...

Avstämningsdag för sammanläggning av aktier i Qlife Holding AB

Styrelsen i Qlife Holding AB (publ) (”Qlife” eller ”Bolaget”) har, med stöd av bemyndigandet från årsstämman som hölls den 26 juni 2024, bes...

Qlife participates research trial for people living with PKU and gets positive data

Qlife has participated a research trial at Emory University (USA) focused on young women living with PKU (phenylketonuria) and made Egoo sys...

Qlife participates research trial for people living with PKU and gets positive data

Qlife has participated a research trial at Emory University (USA) focused on young women living with PKU (phenylketonuria) and made Egoo sys...

Kommuniké från årsstämma 2024 i Qlife Holding AB

Kommuniké från årsstämma 2024 i Qlife Holding AB

Kommuniké från årsstämma 2024 i Qlife Holding AB

Kommuniké från årsstämma 2024 i Qlife Holding AB

Qlife Holding AB loses arbitration proceedings against Aidian

Qlife Holding AB loses arbitration proceedings against Aidian

Qlife Holding AB loses arbitration proceedings against Aidian

Qlife Holding AB publishes information by reason of ongoing negotiations with Atlas Special Opportunities, LLC, regarding a financing solution

Qlife Holding AB publishes information by reason of ongoing negotiations with Atlas Special Opportunities, LLC, regarding a financing soluti...

Qlife Holding AB publishes information by reason of ongoing negotiations with Atlas Special Opportunities, LLC, regarding a financing solution

Qlife Holding AB: The exercise period for warrants series TO 4 in Qlife Holding begins today

The exercise period for warrants series TO 4 that were issued in conjunction with Qlife Holding AB's ("Qlife" or the "Company") rights issue...

Qlife Holding AB: The exercise period for warrants series TO 4 in Qlife Holding begins today

The exercise period for warrants series TO 4 that were issued in conjunction with Qlife Holding AB's ("Qlife" or the "Company") rights issue...

Qlife Holding AB publishes 2023 annual report

Qlife Holding AB’s (“Qlife”) annual report has been published on Qlife’s website as of today, https://qlifeholding.

Qlife Holding AB publicerar årsredovisning för 2023

Qlife Holding AB:s (“Qlife”) årsredovisning finns från och med idag tillgänglig på Qlifes hemsida, https://qlifeholding.

Qlife starts clinical trial in China with first biomarker on Egoo Health

Qlife and its partner Hipro Biotechnology have validated performance of the first biomarker C-Reactive Protein and are now starting clinical...

Qlife starts clinical trial in China with first biomarker on Egoo Health

Qlife and its partner Hipro Biotechnology have validated performance of the first biomarker C-Reactive Protein and are now starting clinical...

QLIFE HOLDING AB, Interim Report Q1, January to March 2024

Standing firm and moving forward

QLIFE HOLDING AB, Interim Report Q1, January to March 2024

Standing firm and moving forward

Kallelse till årsstämma 2024 i Qlife Holding AB

Aktieägarna i Qlife Holding AB, org.nr 559224-8040, kallas till årsstämma den 26 juni 2024 kl.

Kallelse till årsstämma 2024 i Qlife Holding AB

Aktieägarna i Qlife Holding AB, org.nr 559224-8040, kallas till årsstämma den 26 juni 2024 kl.

Qlife Holding AB enters into an addendum with the holders of the company’s convertible debentures and all outstanding convertible debentures are converted into shares

Qlife Holding AB (“Qlife” or the “Company”) has today entered into an addendum with the holders of the Company’s outstanding convertible deb...

Qlife Holding AB enters into an addendum with the holders of the company’s convertible debentures and all outstanding convertible debentures are converted into shares

Qlife Holding AB (“Qlife” or the “Company”) has today entered into an addendum with the holders of the Company’s outstanding convertible deb...

Bulletin from the extraordinary general meeting, and the first meeting for liquidation purposes, in Qlife Holding AB on 23 April 2024

Today, on 23 April 2024, an extraordinary general meeting, and the first meeting for liquidation purposes, was held in Qlife Holding AB.

Bulletin from the extraordinary general meeting, and the first meeting for liquidation purposes, in Qlife Holding AB on 23 April 2024

Today, on 23 April 2024, an extraordinary general meeting, and the first meeting for liquidation purposes, was held in Qlife Holding AB.

CORRECTION Qlife informs that it has put its Danish operational company into reconstruction mode as a temporary measure

CORRRECTION, previous version should have had a MAR-legend, below corrected.

CORRECTION Qlife informs that it has put its Danish operational company into reconstruction mode as a temporary measure

CORRRECTION, previous version should have had a MAR-legend, below corrected.

Qlife informs that it has put its Danish operational company into reconstruction mode as a temporary measure

Under Danish law the company can during a reconstrution phase resolve on creditor issues and access certain loans.

Qlife informs that it has put its Danish operational company into reconstruction mode as a temporary measure

Under Danish law the company can during a reconstrution phase resolve on creditor issues and access certain loans.

Qlife announces the last day for trading in BTU and the first day for trading in warrants series TO 4 and TO 5

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

Qlife announces the last day for trading in BTU and the first day for trading in warrants series TO 4 and TO 5

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

UPDATE: Qlife is emphasizing its strategy to finalize regulatory and Go-To-Market in China, register in Asian countries through partners, and then file for approval in the UK and EU

UPDATE: Qlife is emphasizing its strategy to finalize regulatory and Go-To-Market in China, register in Asian countries through partners, an...

UPDATE: Qlife is emphasizing its strategy to finalize regulatory and Go-To-Market in China, register in Asian countries through partners, and then file for approval in the UK and EU

UPDATE: Qlife is emphasizing its strategy to finalize regulatory and Go-To-Market in China, register in Asian countries through partners, an...

Qlife signs letter of intent with South Korean company Precision Biosensor as part of B2B strategy to enter major markets with Egoo Health, through hospital@home partnerships

Qlife signs letter of intent with South Korean company Precision Biosensor as part of B2B strategy to enter major markets with Egoo Health, ...

Qlife signs letter of intent with South Korean company Precision Biosensor as part of B2B strategy to enter major markets with Egoo Health, through hospital@home partnerships

Qlife signs letter of intent with South Korean company Precision Biosensor as part of B2B strategy to enter major markets with Egoo Health, ...

Notice of extraordinary general meeting, and the first meeting for liquidation purposes, in Qlife Holding AB

Notice of extraordinary general meeting, and the first meeting for liquidation purposes, in Qlife Holding AB

Notice of extraordinary general meeting, and the first meeting for liquidation purposes, in Qlife Holding AB

Notice of extraordinary general meeting, and the first meeting for liquidation purposes, in Qlife Holding AB

UPDATE: Qlife is emphasizing that the call today for an extraordinary general meeting (EGM) is a necessity according to Swedish law, but that the company otherwise is following its plans.

UPDATE: Qlife is emphasizing that the call today for an extraordinary general meeting (EGM) is a necessity according to Swedish law, but tha...

UPDATE: Qlife is emphasizing that the call today for an extraordinary general meeting (EGM) is a necessity according to Swedish law, but that the company otherwise is following its plans.

UPDATE: Qlife is emphasizing that the call today for an extraordinary general meeting (EGM) is a necessity according to Swedish law, but tha...

Qlife has prepared a balance sheet for liquidation purposes and the board of directors will convene an extraordinary general meeting (for liquidation purposes)

The board of directors of Qlife Holding AB ("Qlife" or the "Company"), has, in accordance with Chapter 25, Section 13 of the Swedish Compani...

Qlife has prepared a balance sheet for liquidation purposes and the board of directors will convene an extraordinary general meeting (for liquidation purposes)

The board of directors of Qlife Holding AB ("Qlife" or the "Company"), has, in accordance with Chapter 25, Section 13 of the Swedish Compani...

Qlife publishes outcome in rights issue

On 12 December 2023, Qlife Holding AB (“Qlife” or the “Company”) announced a rights issue of units of approximately SEK 49.

Qlife publishes outcome in rights issue

On 12 December 2023, Qlife Holding AB (“Qlife” or the “Company”) announced a rights issue of units of approximately SEK 49.

The subscription period in Qlife’s rights issue ends on Monday, February 26, 2024

Monday, February 26, 2024, is the last day of the subscription period in Qlife Holding AB’s (“Qlife” or the “Company”) rights issue of units...

The subscription period in Qlife’s rights issue ends on Monday, February 26, 2024

Monday, February 26, 2024, is the last day of the subscription period in Qlife Holding AB’s (“Qlife” or the “Company”) rights issue of units...

Qlife’s core patent granted in Europe

Qlife announces that its core patent for the Egoo system has been granted in the EU and other countries in the European market, as well as i...

Qlife’s core patent granted in Europe

Qlife announces that its core patent for the Egoo system has been granted in the EU and other countries in the European market, as well as i...

Qlife reports first milestone achieved and on track with Chinese collaboration

UPDATE: Qlife has previously reported the potential of its Chinese collaboration and is now updating accordingly: Qlife’s collaboration with...

Qlife reports first milestone achieved and on track with Chinese collaboration

UPDATE: Qlife has previously reported the potential of its Chinese collaboration and is now updating accordingly: Qlife’s collaboration with...

The subscription period in Qlife’s rights issue begins today

Today, February 12, 2024, is the first day of the subscription period in Qlife Holding AB’s (“Qlife” or the “Company”) issue of a maximum of...

The subscription period in Qlife’s rights issue begins today

Today, February 12, 2024, is the first day of the subscription period in Qlife Holding AB’s (“Qlife” or the “Company”) issue of a maximum of...

Qlife publishes prospectus due to upcoming rights issue of units

The board of directors of Qlife Holding AB ("Qlife" or the "Company") has, in connection with the Company's upcoming rights issue of units t...

Qlife publishes prospectus due to upcoming rights issue of units

The board of directors of Qlife Holding AB ("Qlife" or the "Company") has, in connection with the Company's upcoming rights issue of units t...

CORRECTION Qlife Q4 2023

Earlier press release did not include the CEO statement and should have been marked with the MAR legend as it contains insider information.

CORRECTION Qlife Q4 2023

Earlier press release did not include the CEO statement and should have been marked with the MAR legend as it contains insider information.

QLIFE HOLDING AB, Interim Report Q4, January to December 2023

Looking ahead with new partners

QLIFE HOLDING AB, Interim Report Q4, January to December 2023

Looking ahead with new partners

Qlife postpones the publication of the year-end report for the financial year 2023 until 8 February 2024

Qlife Holding AB has decided to postpone the publication of the year-end report for the financial year 2023.

Qlife postpones the publication of the year-end report for the financial year 2023 until 8 February 2024

Qlife Holding AB has decided to postpone the publication of the year-end report for the financial year 2023.

Bulletin from the extraordinary general meeting in Qlife Holding AB on 16 January 2024

Today, on 16 January 2024, an extraordinary general meeting was held in Qlife Holding AB.

Notice of extraordinary general meeting in Qlife Holding AB

The shareholders of Qlife Holding AB, Reg. No. 559224-8040, are hereby invited to attend the extraordinary general meeting to be held on Tue...

Qlife carries out a rights issue of units of approximately SEK 49.5 million

Today, the board of directors in Qlife Holding AB (“Qlife” or the “Company”) has, subject to approval by the extraordinary general meeting o...

Qlife carries out a rights issue of units of approximately SEK 49.5 million

Today, the board of directors in Qlife Holding AB (“Qlife” or the “Company”) has, subject to approval by the extraordinary general meeting o...

Qlife collaboration agreement with Hipro biotechnology - potential value of 500 MSEK

Qlife has received many questions related to the potential value of the agreement, and consequently updates as follows:

Qlife collaboration agreement with Hipro biotechnology - potential value of 500 MSEK

Qlife has received many questions related to the potential value of the agreement, and consequently updates as follows:

Qlife signs collaboration agreement with Hipro Biotechnology

Qlife has recently announced the signing of a Letter of Intent (LOI) with a leading industry partner, Hipro Biotechnology, as a component of...

Management changes in Qlife Holding AB

Qlife Holding AB is pleased to announce the appointment of Peter Thorsen as the new Chief Financial Officer (CFO) of the company, effective ...

Qlife Holding AB, Interim report Q3, January to September 2023

Looking ahead with new partners